Celsion Corporation (CLSN) Stock: Gaining On Ovarian Cancer Results


Celsion Corporation (NASDAQ: CLSN) is off to an incredibly strong start to the trading session today, and for good reason. The company announced the results from a Phase 1b clinical trial, which proved to be positive. This led to excitement among investors who are sending the stock soaring as we speak. As is normally the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (10:15), CLSN is trading at $4.62 per share after a gain of $1.96 per share (73.80%) thus far today.

CLSN Gains On Positive Trial Results

As mentioned above, Celsion Corporation is having an incredibly strong time in the market at the moment after releasing the results from a recent clinical trial. The Phase 1b clinical trial was designed to evaluate a treatment for ovarian cancer. The treatment known as Gen-1 is a DNA-based immunotherapy that is added to the standard care for patients with advanced ovarian cancer who will undergo chemotherapy followed by surgery.

The results that were released show that out of 14 patients that were treated, 2 achieved a complete response, 10 achieved a partial response, and 2 remained stable. As a result, a 100% disease control rate (DCR) was achieved. This comes along with an 86% objective response rate (ORR).

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLSN. In particular, we’re interested in following the company’s ongoing work with regard to Gen-1. We’ll continue following the story and bringing the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here